Sun Pharma Inks Agreement With US-Based Pharmazz on Cerebral Ischemic Stroke Drug

According to the agreement, Sun Pharma has been granted the rights to market Sovateltide in India under the brand name Tyvalzi (Sovateltide). USA's Pharmazz will receive upfront and milestone payments, including royalties as a part of the agreement. 

The Indian multinational pharmaceutical company, Sun Pharmaceutical has entered into a licence agreement with US-based Pharmazz Inc. to commercialise Tyvalzi (Sovateltide), in India.

Sovateltide, developed by the US biopharmaceutical company, is designed for the treatment of cerebral ischemic stroke. 

Under this agreement, Sun Pharma has been granted the rights to market Sovateltide in India under the brand name Tyvalzi (Sovateltide). Moreover, USA's Pharmazz will receive upfront and milestone payments, including royalties as a part of the agreement. 

Sharing her views, Kirti Ganorkar, chief executive (India Business), Sun Pharma,  said, 'œThe Phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke. Tyvalzi is a first-in-class novel drug that can help improve the quality of life of stroke patients. The drug can be administered within 24 hours for the treatment of ischemic stroke. The current treatment options provide a narrow time window of 4-5 hours limiting its use in most patients.'

According to a Hindu Businessline report, studies suggest that the occurrence of stroke in India ranges from 116 to 163 per 100,000 population. Furthermore, stroke ranks as the fourth leading cause of death and the fifth leading cause of disability in India. 

Further estimates indicate that by 2050, low and middle-income countries will experience over 80% of the projected worldwide increase in stroke cases, totalling 15 million.

Dr. Prof Anil Gulati, inventor, CEO, and Chairman of the Board of Directors of Pharmazz, said, 'œFor patients with cerebral ischemic stroke, I believe Sun Pharma is the best partner for Pharmazz to market TyvalziTM (Sovateltide), a first-in-class novel treatment for cerebral ischemic stroke, in India.'

He further added that Sovateltide (TyvalziTM) produced statistically significant and clinically meaningful improvements in neurological outcomes at 90 days post-treatment in clinical trials as measured by the NIHSS, mRS, and B.I. scales. 

Founded in 1983, Sun Pharmaceutical Industries Limited, also known as Sun Pharma, is the proprietor of the brand name Tyvalzi, which is a pioneering drug for treating acute cerebral ischemic stroke, a condition where reduced blood supply to the brain can lead to brain damage, neurological issues, or even death. 

Additionally, Tyvalzi has the ability to work on neural progenitor cells, promoting the growth of new neurons and blood vessels while safeguarding neural mitochondria and supporting their development.

With this initiative, the Mumbai-based Indian multinational pharmaceutical company aims to provide high-quality, affordable medicines trusted by healthcare professionals and patient